Navigation Links
Adult COPD or asthma could be effectively treated with Xopenex

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic lung disease caused by inflammation of the lower airways resulting in episodes of airflow obstruction, which has been found to be the fourth most common// cause of death and affects nearly 16 million people in the United States. According to the American Lung Association, it is the most common childhood illness and affects approximately 8.6 million children under the age of 18.

A new study conducted at the Halifax Regional Hospital in South Boston, suggested Xopenex as a viable first-line therapy for hospitalized adult COPD or asthma patients. Lead author of the study, Terrance Truitt said that Xopenex is safe in a hospital setting, and is an effective alternative to racemic albuterol in treating the bronchial smooth muscle spasm associated with diseases such as COPD and asthma. The study involved the comparison of the treatment of 231 patients with similar background and disease conditions over two separate six-month periods. The first group had been treated with the previous standard treatment, the second group with Xopenex. It was found that the subjects showed significant symptom improvement and a change in the frequency of nebulizer treatments - in intervals of 6 to 8 hours. This change was achieved with a 1.25 mg dose of Xopenex. In addition, the Xopenex group needed only 2.0 +/- 2.6 days of ipratropium bromide treatments. Patients receiving Xopenex were found to require significantly less nebulizer therapy and less adjuvant respiratory therapy, according to the study.

Xopenex is being marketed as a nebulizer at dosage strengths of 0.31 mg and 0.63 mg for pediatric patients and as 0.63 mg and 1.25 mg for patients 12 years of age and older. Xopenex brand levalbuterol HCl inhalation solution is indicated for the treatment or prevention of bronc hospasm in patients 6 years and older with reversible obstructive airway disease, such as asthma.


Related medicine news :

1. Baby Talk Better Than Adult Speech
2. A question on study of Adult Stem Cell
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. The Key To Prevention Of Heart Disease In Adults
5. The Harmful Effects Of Stress in Young Adults
6. Abuse in Childhood Could Result In Heart Disease in Adulthood
7. Adult bone health is dependent on lifestyle we live
8. Adult Stem Cells From Fat Tissues For Healing
9. Obese Adults Undergo Less Medical Tests And More Vulnerable To Diseases
10. A New Technique For Prediction Of Adult Height
11. New Drug Found To Improve Driving Performance In Young Adults With ADHD
Post Your Comments:

(Date:11/26/2015)... Karnataka (PRWEB) , ... November ... ... innovative online platform for mental health and wellness consultation, has collaborated with ... to holistically address their reader’s queries on topics on mental and emotional ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
(Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published ... and more widely heralded as a breakthrough for performing hernia repairs. The article explains ... laparoscopic surgery is that it can greatly reduce the pain that a patient might ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... of self-monitoring blood glucose devices was valued at $11,171.1 ... with a CAGR of 5.7% during 2015 - 2022. ... population and increasing prevalence of diabetes. In addition, the ... care is also contributing to the growth of the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
Breaking Medicine Technology: